Re: 18 F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial

Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research

Related Links:

This report describes 2 patients with UC in whom postoperative pain following oral and maxillofacial surgery was managed by intravenous patient-controlled analgesia with pentazocine. Apart from the development of acute dystonia in 1 case that was likely due to the use of droperidol for prevention of postoperative nausea and vomiting, postoperative pain was well controlled by pentazocine in both patients without any complications or UC exacerbations. PMID: 32992337 [PubMed - in process]
Source: Anesthesia Progress - Category: Anesthesiology Tags: Anesth Prog Source Type: research
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
This study aimed to identify the feasibility and predictors of achieving histologic remission in patients with ulcerative colitis treated-to-target of endoscopic healing.Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Publication date: Available online 28 September 2020Source: Chemico-Biological InteractionsAuthor(s): Omaima A. Ahmedy, Sherehan M. Ibrahim, Heba H. Salem, Esraa A. Kandil
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
No abstract available
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Images Source Type: research
(University of California - Riverside) A team of researchers led by biomedical scientist Declan McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine. " Our work could help improve identification of patients who will be better responders to this drug, " says McCole, a professor of biomedical sciences in the School of Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Differentiating between ulcerative colitis (UC), Crohn ’s disease (CD) and intestinal tuberculosis (ITB) using endoscopy is challenging. We aimed to realize automatic differential diagnosis among these diseases...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Research article Source Type: research
Endoscopic remission is a recognized therapeutic endpoint in inflammatory bowel disease (IBD; Crohn ’s disease (CD), ulcerative colitis (UC)). The impact of persistent histologic activity on long-term outcomes is less clear and limited by small studies.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
How effective is hyperbaric oxygen for improving outcomes in hospitalized ulcerative colitis patients with acute moderate-severe flares refractory to standard medical therapy?Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
We report a case of long-standing ulcerative colitis with intramucosal well- and poorly differentiated adenocarcinomas detected over a 6-month duration. A Japanese man in his sixties with a 31-year history of ulcerative colitis had a 1.1-cm-sized intramucosal well-differentiated tubular adenocarcinoma in the rectum resected by endoscopic submucosal dissection. At the follow-up colonoscopy, a biopsy near the endoscopic submucosal dissection scar revealed poorly differentiated adenocarcinoma, and a total proctocolectomy was performed 6 months after the endoscopic submucosal dissection. The whole colorectal pathological exam ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Inflammatory Bowel Disease | Nuclear Medicine | Ulcerative Colitis